The price of Exelixis Inc (NASDAQ:EXEL) shares last traded on Wall Street rose 5.58% to $20.99.
Based on available information, 19 analysts follow Exelixis Inc (NASDAQ:EXEL). The consensus rating among analysts is ‘Overweight’. EXEL stock price is now -3.10% away from the 50-day moving average and 7.87% away from the 200-day moving average. The market capitalization of the company currently stands at $6.68B.
Among analysts, 4 rate the stock a hold while 13 rate it a buy.
With the price target of $28, H.C. Wainwright recently initiated with Buy rating for Exelixis Inc (NASDAQ: EXEL).
In other news, Aftab Dana, CSO/EVP Disc & Trans Research sold 4,600 shares of the company’s stock on Aug 30. The stock was sold for $103,362 at an average price of $22.47. Upon completion of the transaction, the CSO/EVP Disc & Trans Research now directly owns 399,943 shares in the company, valued at $8.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 04, EVP and CFO Senner Christopher J. sold 60,000 shares of the business’s stock. A total of $1,240,800 was realized by selling the stock at an average price of $20.68. This leaves the insider owning 571,631 shares of the company worth $12.0 million. Insiders disposed of 1,555,504 shares of company stock worth roughly $32.65 million over the past 1 year. A total of 3.52% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EXEL stock. A new stake in Exelixis Inc shares was purchased by PSQUARED ASSET MANAGEMENT AG during the first quarter worth $29,533,000. 13D MANAGEMENT LLC invested $7,430,000 in shares of EXEL during the first quarter. In the first quarter, UNISUPER MANAGEMENT PTY LTD acquired a new stake in Exelixis Inc valued at approximately $6,352,000. WOODLINE PARTNERS LP acquired a new stake in EXEL for approximately $5,436,000. KEPOS CAPITAL LP purchased a new stake in EXEL valued at around $5,248,000 in the second quarter. In total, there are 533 active investors with 85.68% ownership of the company’s stock.
A candlestick chart of Exelixis Inc (NASDAQ: EXEL) showed a price of $19.91 on Thursday morning. During the past 12 months, Exelixis Inc has had a low of $15.32 and a high of $22.80. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 4.68, and a quick ratio of 4.60. According to the stock market information, the enterprise value for the company is $5.26B, which is based on a 41.76 price-to-earnings ratio, a 0.91 price-to-earnings-growth ratio, and a beta of 0.60. The fifty day moving average price for EXEL is $21.65 and a two-hundred day moving average price translates $19.48 for the stock.
The latest earnings results from Exelixis Inc (NASDAQ: EXEL) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.25, beating analysts’ expectations of $0.16 by 0.09. This compares to $0.22 EPS in the same period last year. The net profit margin was 9.58% and return on equity was 6.68% for EXEL. The company reported revenue of $469.85 million for the quarter, compared to $419.43 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 12.02 percent. For the current quarter, analysts expect EXEL to generate $472.21M in revenue.
Exelixis Inc(EXEL) Company Profile
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin’s lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
